pharm - onc

Question 1

vinca alkaloids and taxols effect what part of the cell cycle

Answer 1

M

Question 2

antmetabolites effect what part of the cell cycle

Answer 2

S (DNA sythesis)

Question 3

etoposide effects effect what part of the cell cycle

Answer 3

S (DNA synth) and G2 (synthesis of compenents needed for Mitosis)b

Question 4

bleomycin effect what part of the cell cycle

Answer 4

G2 (synthesis of compenents needed for Mitosis)

Question 5

drugs effecting thymidine synth

Answer 5

MTX, 5-FU,

Question 6

drugs effecting purine synth

Answer 6

6-MP

Question 7

drugs effecting DNA cross-linking

Answer 7

alkalyating agents, cisplatin

Question 8

drugs that intercalate DNA

Answer 8

dactomycin, doxurubin

Question 9

drugs that inhibit topoisomerase

Answer 9

etoposide

Question 10

drugs that inhibit microtubule formatino

Answer 10

vinca alkaloids

Question 11

drugs that inhibt microtubule dissaebmly

Answer 11

paclitaxel

Question 12

MOA of MTX

Answer 12

folic acid analog - inhibts dihydrofolate reductace –>

Question 13

effect of MTX

Answer 13

inhibits DNA and protein synth

Question 14

use of MTX

Answer 14

blood cancers, choricocarcinomas

Question 15

non cancer use of MTX

Answer 15

abortion, ectopic, RA, psoriasis

Question 16

tox of MTX

Answer 16

myeosuppression, fatty liver, mucositis, birth defects

Question 17

“rescue” of MTX

Answer 17

leucovorin

Question 18

5-FU MOA

Answer 18

pyramidine analog converted to 5f-dUMP - complexes folic acid

Question 19

effect of 5-FU

Answer 19

inhibits DNA and protein synth

Question 20

use of 5-FU

Answer 20

colon cancer, basal cell carcinoma

Question 21

tox of 5-FU

Answer 21

myleosuppression , photosensitivity

Question 22

rescue of 5-FU

Answer 22

thymidine

Question 23

MOA of cytarabine

Answer 23

pyramdine analog, inhibits DNA polymerase

Question 24

use of cytarabine

Answer 24

blood cancers

Question 25

tox of cytarabine

Answer 25

leukopenia, thrombocytopenia, megaloblastic anemia

Question 26

6-MO/6-TG/azathrioprine MOA

Answer 26

purine anologs --> inhibit de novo purine synth

Question 27

use of 6-MO/6-TG/azathrioprine

Answer 27

leukemia

Question 28

6-MO/6-TG/azathrioprine tox

Answer 28

bone marrow, GI and liver tox | reacts with allopurinol

Question 29

dactinomycin MOA

Answer 29

intercalates in DNA

Question 30

use of dactinomycin

Answer 30

kids tumors

Question 31

Tox od dactinomycin

Answer 31

myleosupression

Question 32

doxirubicin MOA

Answer 32

generates free radicals, breaks DNA

Question 33

use of doxirubicin

Answer 33

solid tumors, blood cancers

Question 34

SE of doxirubicin

Answer 34

dilatated cardiomyopathy myleosuppression alopecia can be toxic to exposed tissues

Question 35

used to chelate doxirubicin from heart

Answer 35

dexrazoxane

Question 36

bleolycin MOA

Answer 36

induces free radicals

Question 37

Bleomycin use

Answer 37

testicular cancer, hodgkin's lymphoma

Question 38

bleomycin tox

Answer 38

pulmonanry fibrosis skin changes some myleosuppression

Question 39

cylcophosphamide MOA

Answer 39

interstrands DNA at guinine (must be activated by liver)

Question 40

use of cylcophosphamide

Answer 40

brain tumors

Question 41

SE of cylcophosphamide

Answer 41

CNS tox

Question 42

busulfan MOA

Answer 42

alklylates DNA

Question 43

busulfan use

Answer 43

CML (and ablates pts marrow before transplantation)

Question 44

Busulfan tox

Answer 44

pulmonary fibrosis

Question 45

vincristine/vinblastine MOA

Answer 45

bind to tubulin in M phase and blowck microtubules. mitoic spindle cannot form

Question 46

use of vincristine/vinblastine

Answer 46

solid tumors, blood cancer

Question 47

tox of vincristine

Answer 47

neurotox (areflexia,pripheral neutitis, paralytic ileus)

Question 48

tx of vinblastine

Answer 48

severe bone marrow suppression

Question 49

MOA of taxols

Answer 49

hyperstabalizes microtubules so the mitotic spindle cannot break down --> no anaphase

Question 50

use of taxols

Answer 50

ovarian and breast carcinoma

Question 51

tox of taxols

Answer 51

myleosuppression and hypersensitivity

Question 52

MOA of cisplatin/carboplatin

Answer 52

cross-links DNA

Question 53

use of cisplatin/carboplatin

Answer 53

testicular, bladder,ovary, and lung carcinomas

Question 54

tox of cisplatin/carboplatin

Answer 54

nephro.ototox

Question 55

prevent nephrotix in cisplatin/carboplatin with

Answer 55

amifostine ad chloride diuresis

Question 56

etoposide, teniposide MOA

Answer 56

inhibit topiisomerase II

Question 57

use of etoposide, teniposide

Answer 57

solid tumors, blood cancers

Question 58

tox of etoposide, teniposide

Answer 58

myleosuppression, GI irritation, alopecia

Question 59

hydroxyurea MOA

Answer 59

inhibits ribonucleotide reductase --> inhibits S phase DNA synthesis

Question 60

use of hydroxyurea

Answer 60

melanoma, CML, sickle cell

Question 61

tox of hydroxyurea

Answer 61

bone marrow suppression, GI upset

Question 62

cancer use of predisone

Answer 62

CLL, non-HL,

Question 63

tamoxifen MOA

Answer 63

SERM. Blocks estrogen binding in estrogen receptor + cells

Question 64

use of tamoxifen

Answer 64

breast cancer tx and prevention - also prevents osteoporosis

Question 65

tox of tamoxfen

Answer 65

can increase risk of endometrial cancer

Question 66

SERM that does in increase risk of endometrial cancer

Answer 66

raloxafine

Question 67

trastuzumab MOA

Answer 67

monoclonal antobody against HER-2

Question 68

use of trastuzumab

Answer 68

MER-2 + breast cancer

Question 69

tox of trastuzumab

Answer 69

cardiotox

Question 70

imatinb (Gleevec) MOA

Answer 70

philly chromosome TK inhibitor

Question 71

use of imatinb (Gleevec)

Answer 71

CML, GI stromal tumors

Question 72

tox of imatinb (Gleevec)

Answer 72

fluid retention

Question 73

rituximab MOA

Answer 73

monoclonal antobody against CD-20 on B cells

Question 74

use of rituximab

Answer 74

NHL, RA (with MTX)

Question 75

vemurafenib MOA

Answer 75

inhibis B-Raf kinase with v600E mutation

Question 76

vemurafenib use

Answer 76

metastatic melanoma

Question 77

bevacizumab MOA

Answer 77

monoclonal antibody against VEGF (inhibts angiogenesis)

Question 78

bevacizumab use

Answer 78

solid tumors